US President Donald Trump on Monday hinted at a possible retaliation if India does not lift its hold on the export of Hydroxychloroquine, the anti-malaria drug used in the treatment of coronavirus patients.
Trump speaking from the White House during the Coronavirus taskforce briefing said that India does very well with the US and he sees no reason why India would not lift the hold on the US order of the medicine.
He said, "'didn't hear that that was his (Modi) decision. I know that he stopped it for other countries I spoke to him yesterday, very very good talk, and we'll see whether or not that stays I wouldn't be surprised if he would you know because India's does very well with the United States,"
Trump said that during his recent phone call with Modi, the latter had said he will consider the request of releasing the order to the US.
The US President added, "So I wouldn't be surprised if that was a decision he'd have to tell me that I spoke to him Sunday morning I called him and I said we'd appreciate your allowing our supply to come out. If he doesn't allow it to come out,"
Trump said that India and the US have had good trade agreements and hinted at possible retaliation if India decided not to lift the hold. US President Donald Trump on Saturday had said that he has requested Prime Minister Narendra Modi to supply Hydroxychloroquine tablets that can be used to treat COVID-19 patients.
"After call today with Indian Prime Minister Narendra Modi, India is giving serious consideration to releasing the hold it put on a US order for hydroxychloroquine," Trump announced at the White House Coronavirus task force briefing.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
